[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,266
Citations 0
News From the Food and Drug Administration
February 6, 2018

New Human Insulin Analog Approved

JAMA. 2018;319(5):434. doi:10.1001/jama.2017.21720

The FDA has approved another formulation of insulin lispro—a type of rapid-acting human insulin analog—to improve glycemic control in adults and children aged 3 years or older with type 1 diabetes and in adults with type 2 diabetes. Marketed as Admelog, the product is a follow-on drug approved through an abbreviated pathway that relied in part on its similarity to Humalog, an insulin lispro approved in 1996.